Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study Positive results could support the initiation of a pivotal Phase 3 ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 ...

FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

Approvable population of ulcerative colitis (UC) patients for upcoming Phase 3 trials agreed upon with the U.S. Food and Drug Administration (FDA) Analysis of Phase 2 data using approvable UC patient ...

Over the past decade, industry-sponsored clinical trial activity at UAB has grown steadily. To sustain and accelerate this momentum, the Clinical Trialist Development Program (CTDP) supports promising ...

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / ...

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology * Lead progra ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing peptide-based drugs, stands at a pivotal juncture in its ...